Research programme: genetically modified skin replacement therapy - Stratatech

Drug Profile

Research programme: genetically modified skin replacement therapy - Stratatech

Alternative Names: EpiReady; ExpressGraft™; ExpressGraft™ - Antineoplastic; ExpressGraft™ - Pro-angiogenic; ExpressGraft™ Enhance

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer Stratatech
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cathecilidin expression stimulants; Gene transference; Interleukin-12 expression stimulants; Tissue replacements; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Skin cancer
  • No development reported Skin ulcer

Most Recent Events

  • 31 Aug 2016 Stratatech has been acquired by Mallinckrodt plc
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-ulcer in USA (Topical, Patch)
  • 05 Aug 2013 Early research in Skin cancer in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top